Article in PLoS biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Tudor I OpreaDepartment of Internal Medicine, Comprehensive Cancer Center, University of New Mexico School of Medicine, Albuquerque New Mexico, United States of America.
Lily JanDepartment of Physiology, University of California-San Francisco, San Francisco, California, United States of America.
Gary L JohnsonDepartment of Pharmacology, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Bryan L RothDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Avi Ma'ayanDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.ORCID 0000-0002-6904-1017
Stephan SchürerDepartment of Pharmacology, Miller School of Medicine, Center for Computational Science, University of Miami, Miami, Florida, United States of America.
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, United States of America.
Larry A SklarDepartment of Pathology, Comprehensive Cancer Center, University of New Mexico School of Medicine, Albuquerque, New Mexico, United States of America.ORCID 0000-0002-8196-5060
Michael T McManusDepartment of Microbiology and Immunology, UCSF Diabetes Center, University of California-San Francisco, San Francisco, California, United States of America.ORCID 0000-0003-3013-6569
Funding
Illuminating the Druggable GPCR-omeU24DK116195 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L., SHOICHET, BRIAN K · 2017 to 2022
$14.3M
Illuminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6M
Illuminating Druggable Dark MatterU24DK116214 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAN, LILY Y, MCMANUS, MICHAEL T · 2017 to 2022
$12.9M
Machine Learning Model Validation for AD/ADRDU24CA224370 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI EDWARDS, JEREMY S · 2018 to 2023
$6.4M
Resource Dissemination and Outreach Center for Illuminating the Druggable GenomeU24TR002278 · NCATS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SCHURER, STEPHAN C, SKLAR, LARRY A. · 2018 to 2023
$3.7M
Knowledge Management Center for Illuminating the Druggable GenomeU24CA224260 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MA'AYAN, AVI · 2018 to 2023
This Formal Comment responds to a recent Meta-Research Article by identifying initiatives that are already in place for funding risky exploratory research that illuminate mysteries of the dark genome.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Far away from the lamppost. · full record | OpenQuestion